Xenetic’s Dr. Reid Bissonnette Discusses Exciting Preclinical Data at SITC Spring Scientific 2025
Xenetic Biosciences, a pioneering biopharmaceutical company specializing in innovative immune-oncology technologies for hard-to-treat cancers, recently unveiled promising preclinical findings at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting. Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, participated in a Virtual Investor “What This Means” segment to discuss the key takeaways from the Company’s poster presentation.
Poster Presentation: “DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma”
The presentation, titled “DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma,” highlighted the potential of Xenetic’s proprietary DNase I technology to improve the efficacy of CAR-T cell therapy in treating solid tumors, specifically metastatic melanoma. Neutrophil Extracellular Traps (NETs) are complex structures formed by neutrophils to trap and kill pathogens. However, they can also obstruct the function of therapeutic agents, including CAR-T cells, leading to treatment failure in solid tumors.
Dr. Bissonnette explained that Xenetic’s DNase I technology selectively breaks down NETs, allowing CAR-T cells to penetrate and effectively target cancer cells. Preclinical data presented at the meeting demonstrated significant improvements in tumor regression and survival in mouse models of metastatic melanoma treated with Xenetic’s DNase I-enhanced CAR-T cells compared to control groups.
Implications for Patients and the World
Patients: This groundbreaking research could pave the way for more effective CAR-T cell therapies for patients with solid tumors, particularly those with metastatic melanoma. By addressing the challenge of NETs and their impact on CAR-T cell function, Xenetic’s DNase I technology could lead to better treatment outcomes and improved survival rates.
- Improved tumor regression and survival in preclinical models
- Overcoming the challenge of NETs and their impact on CAR-T cell function
- Potential for more effective CAR-T cell therapies for solid tumors
World: The successful application of Xenetic’s DNase I technology in enhancing the efficacy of CAR-T cell therapy could have a significant impact on the field of cancer immunotherapy. This innovation could lead to more effective treatments for various types of solid tumors, potentially improving the lives of millions of cancer patients worldwide.
- Advancements in cancer immunotherapy
- More effective treatments for solid tumors
- Potential to improve the lives of millions of cancer patients
Conclusion
Xenetic’s participation in the SITC Spring Scientific 2025 Cell Therapy Meeting marked an important milestone in the Company’s mission to advance innovative immune-oncology technologies for hard-to-treat cancers. The preclinical data presented, which highlighted the potential of Xenetic’s DNase I technology to enhance CAR-T cell therapy in solid tumors, could lead to significant improvements in treatment outcomes for patients with metastatic melanoma. This breakthrough innovation could also have a profound impact on the field of cancer immunotherapy, potentially leading to more effective treatments for various types of solid tumors and improving the lives of millions of cancer patients worldwide.
As Xenetic continues to explore the potential of its DNase I technology, the Company is poised to make a significant contribution to the field of cancer research and treatment. The future looks bright for Xenetic and the countless individuals whose lives could be transformed by these groundbreaking discoveries.
